An Ohio State University spinoff developing a treatment for a deadly mitochondrial disease launched Tuesday in Boston with a $59 million round of venture capital investment.
Entrada Therapeutics is using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in the power center of a cell.
Story excerpt provided by Columbus Business First.
Written by Allison DeAngelis.
Originally published December 19, 2018.